- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success | 3 | Zacks | ||
| 16.04. | Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug | 1 | Zacks | ||
| 16.04. | FDA halts Neumora's schizophrenia drug trial over convulsions in rabbits | 2 | Pharmaceutical Technology | ||
| 15.04. | Preclinical Safety Signal Prompts FDA Clinical Hold on Neumora Schizophrenia Drug | 3 | MedCity News | ||
| 15.04. | Neumora's schizophrenia drug hit with clinical hold | 2 | BioPharma Dive | ||
| 15.04. | Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? | 1 | Benzinga.com | ||
| 15.04. | Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug | 1 | Investor's Business Daily | ||
| 15.04. | Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits | 1 | FierceBiotech | ||
| 15.04. | Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? | 1 | InvestorPlace | ||
| 15.04. | Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session | 4 | Benzinga.com | ||
| 15.04. | Neumora Tumbles as Early-Stage Study Put on Clinical Hold | 1 | BNN Bloomberg | ||
| 15.04. | FDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-Market | 1 | RTTNews | ||
| 15.04. | Neumora stock slides as FDA puts Phase 1 schizophrenia study on hold | 1 | Seeking Alpha | ||
| 15.04. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.04. | Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study | 75 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical... ► Artikel lesen | |
| 13.03. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days | 1 | GlobeNewswire (USA) | ||
| 07.03. | Neumora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.03. | Neumora Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 07.03. | Neumora Therapeutics GAAP EPS of -$0.71 | 1 | Seeking Alpha | ||
| 07.03. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,585 | +1,29 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,895 | +1,59 % | Deutsche Bank, Evotec, HelloFresh, Renk, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,500 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| MORPHOSYS | 66,10 | -0,15 % | Novartis-Übernahme läuft: Verlust verzehnfacht: Morphosys muss "Karten auf den Tisch legen" | © Foto: Sven Hoppe/dpaDie geplante Übernahme durch Novartis sorgt für hohe Kosten und lassen die Verluste bei Morphosys explodieren. Für Unruhe sorgt ein Fachartikel zu Sicherheit des Krebsmedikaments... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,43 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SPRINGWORKS THERAPEUTICS | 43,320 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,20 | +2,53 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 19,290 | 0,00 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen | |
| BIONTECH | 85,65 | +2,39 % | Verhaltene Impfstoff-Nachfrage: BioNTech-Konkurrent Moderna: Umsatz bricht um 91 Prozent ein | © Foto: picture alliance / Geisler-Fotopress | Christoph Hardt/Geisler-FotopresTrotz erneut gesunkener Erlöse hat Biotech-Unternehmen Moderna die Erwartungen der Analysten übertreffen können. Dennoch... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 25,580 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| C4 THERAPEUTICS | 6,430 | 0,00 % | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| CG ONCOLOGY | 39,500 | -2,76 % | CG Oncology Inc.: CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 | ||
| ALX ONCOLOGY | 16,620 | -1,89 % | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | ||
| CULLINAN THERAPEUTICS | 27,540 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen |
Das Unternehmen NEUMORA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 9,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
